Leo Pharma completes merger pact with Peplin

Danish LEO Pharma has gained additional ground in the US after finalising the agreement to acquire Australian-US Peplin, Inc.

It was announced that Peplin, Inc and LEO Pharma A/S have completed their definitive merger agreement after obtaining the approval of the majority of stockholders as well as completing the relevant regulatory activities.

The deal was originally announced on 3 September, 2009 when LEO, a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, agreed to acquire all outstanding securities of Peplin for approximately USD 287.5 million in cash.

Peplin will operate as a US-based LEO subsidiary with George Mahaffey, formerly Peplin's chief commercial officer, promoted to lead the company as chief executive officer.